Entyvio is a biologic medication used to treat two forms of inflammatory bowel disease (IBD): ulcerative colitis and Crohn’s disease. It’s FDA-approved for adults with moderately to severely active forms of either condition, meaning it’s typically prescribed when symptoms are significant enough to affect daily life and haven’t responded well to conventional treatments. What makes Entyvio distinct from many other biologics is that it targets inflammation specifically in the gut, rather than suppressing the immune system throughout the entire body.
Conditions Entyvio Treats
Ulcerative colitis and Crohn’s disease are both chronic conditions where the immune system attacks the digestive tract, but they affect it differently. Ulcerative colitis causes inflammation and ulcers in the lining of the colon and rectum. Crohn’s disease can cause deeper inflammation anywhere along the digestive tract, from the mouth to the anus, though it most commonly affects the end of the small intestine and the beginning of the colon.
Entyvio is used for both induction (getting symptoms under control initially) and maintenance (keeping them under control long-term). For Crohn’s disease specifically, the 2025 ACG clinical guidelines also position Entyvio as an option for fistulizing disease and for preventing recurrence after surgery in high-risk patients.
The medication is currently approved only for adults. Pediatric studies for children ages 2 to 17 are still underway, and the FDA has waived the requirement for studies in children under 2 because ulcerative colitis is extremely rare in that age group.
How Entyvio Works
Most biologic therapies for IBD work by dampening immune activity broadly. Entyvio takes a more targeted approach. It blocks a specific protein on the surface of certain immune cells, one that acts like a homing signal directing those cells to travel into the gut lining. By blocking that signal, Entyvio prevents excess immune cells from reaching the intestinal wall, which reduces the inflammation driving symptoms.
This gut-selective mechanism is an important distinction. Because Entyvio only interferes with immune cell movement into the intestines, it leaves immune function in other parts of the body largely intact. Studies have confirmed, for example, that Entyvio does not affect immune cell levels in the brain or spinal fluid, which matters because an older, related drug (natalizumab) carried a meaningful risk of a rare brain infection called progressive multifocal leukoencephalopathy, or PML. Across more than 54,000 patient-years of Entyvio use in clinical trials and post-marketing data, no cases of PML have been reported. If Entyvio carried the same risk as natalizumab, roughly 30 cases would have been expected in that timeframe.
How Well It Works
Entyvio tends to work better for ulcerative colitis than for Crohn’s disease, and it works best in patients who haven’t already tried and failed other biologic therapies. In a large real-world Canadian study tracking over 3,000 patients from 2015 to 2023, remission rates at 14 weeks after starting treatment were 54% for ulcerative colitis and 36% for Crohn’s disease.
Patients who had never used a biologic before generally responded better than those who had previously tried other biologics without success. Among those who needed their dose increased due to a fading response, remission rates 12 weeks later were 43% to 50% for biologic-naive patients versus 23% to 35% for those who had used other biologics previously. These numbers come from clinical symptom scores rather than direct visualization of the gut lining, so they reflect how patients feel day to day rather than endoscopic healing.
How Long It Takes to Work
Entyvio is not a fast-acting medication compared to some other biologics. Many people notice some symptom relief between weeks 2 and 6, but it can take longer. Your doctor will typically evaluate your response around week 14 to determine whether the medication is working well enough to continue. For Crohn’s disease patients who haven’t responded by that point, an additional dose at week 10 is sometimes given before making a final call.
This slower onset means Entyvio may not be the best choice if you need rapid symptom control, but for patients who do respond, it tends to maintain that response well over time.
How It’s Given
Entyvio is available in two forms: intravenous infusion and subcutaneous injection. Most patients start with the IV form, which is given at a clinic or infusion center. The induction schedule involves three infusions: one at the start, another two weeks later, and a third at six weeks. After that, maintenance infusions continue every eight weeks.
Once you’ve completed at least two IV infusions and your doctor is satisfied with your response, you may have the option to switch to self-administered subcutaneous injections at home. The subcutaneous dose is given every two weeks. This can be more convenient than traveling to an infusion center every eight weeks, though some patients prefer the supervised IV setting.
If your response starts to fade over time on the every-eight-week IV schedule, your doctor may shorten the interval to every four weeks before considering a switch to a different medication.
Common Side Effects
The most frequently reported side effects are relatively mild. Nasal congestion or cold-like symptoms (nasopharyngitis) affect about 13% of patients, while headaches and joint pain each occur in roughly 12%. Other common side effects include nausea, fatigue, fever, upper respiratory infections, cough, back pain, and rash.
For patients receiving IV infusions, reactions at the infusion site (pain, irritation, or swelling) can occur but are generally manageable. Skin-related side effects like itching, eczema, or acne are reported in 1% to 10% of patients.
Serious Risks
Because Entyvio modifies immune function, it can reduce your body’s ability to fight certain infections. Serious infections like sepsis are uncommon, occurring in less than 1% of patients. Rare cases of tuberculosis, certain types of meningitis, and liver injury have been reported, though their exact frequency is difficult to pin down.
Liver problems are a known concern. Symptoms to watch for include upper abdominal pain, pale stools, dark urine, loss of appetite, or yellowing of the skin or eyes. These are uncommon but warrant immediate medical attention.
Before starting Entyvio, you’ll need screening tests for tuberculosis and hepatitis B and C. Your doctor will also want to make sure your vaccinations are up to date, since live vaccines cannot be given while you’re on the medication. The shingles vaccine in particular is recommended within the first year of treatment if you haven’t already received it.
Where Entyvio Fits Among IBD Treatments
The treatment landscape for IBD has expanded significantly in recent years. The 2025 ACG guidelines for Crohn’s disease list Entyvio alongside anti-TNF therapies (like infliximab and adalimumab), newer IL-23 inhibitors (like risankizumab and guselkumab), and JAK inhibitors (like upadacitinib). Entyvio’s gut-selective mechanism gives it a favorable safety profile compared to medications that suppress the immune system more broadly, which makes it an appealing option for patients concerned about systemic immunosuppression or those at higher risk for infections.
That said, its slower onset of action and somewhat lower remission rates in Crohn’s disease compared to ulcerative colitis mean it’s not always the first biologic recommended. Where it tends to shine is in ulcerative colitis, in patients who are biologic-naive, and in situations where the safety profile matters most, such as older patients or those with a history of infections or cancer.